Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
RGEN Stock Forecast 2025-2026
$160.81
Current Price
$9.05B
Market Cap
Buy 16
Hold 5
Sell 0
Wall St Analyst Ratings
Distance to RGEN Price Targets
+36.8%
To High Target of $220.00
+16.6%
To Median Target of $187.50
-0.5%
To Low Target of $160.00
RGEN Price Momentum
-2.6%
1 Week Change
+12.6%
1 Month Change
+3.9%
1 Year Change
+11.7%
Year-to-Date Change
-11.9%
From 52W High of $182.52
+56.2%
From 52W Low of $102.97
📊 TOP ANALYST CALLS
Did RGEN Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Repligen is one of their latest high-conviction picks.
Latest RGEN Stock Price Targets & Analyst Predictions
Based on our analysis of 23 Wall Street analysts, RGEN has a bullish consensus with a median price target of $187.50 (ranging from $160.00 to $220.00). The overall analyst rating is Strong Buy (8.9/10). Currently trading at $160.81, the median forecast implies a 16.6% upside. This outlook is supported by 16 Buy, 5 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Paul Knight at Keybanc, projecting a 36.8% upside. Conversely, the most conservative target is provided by Luke Sergott at Barclays, suggesting a 0.5% downside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
RGEN Analyst Ratings
16
Buy
5
Hold
0
Sell
RGEN Price Target Range
Low
$160.00
Average
$187.50
High
$220.00
Current: $160.81
Latest RGEN Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for RGEN.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Oct 29, 2025 | Canaccord Genuity | Kyle Mikson | Hold | Maintains | $165.00 |
| Oct 29, 2025 | Barclays | Luke Sergott | Overweight | Maintains | $175.00 |
| Oct 7, 2025 | Evercore ISI Group | Daniel Markowitz | Outperform | Maintains | $175.00 |
| Oct 2, 2025 | Barclays | Luke Sergott | Overweight | Maintains | $160.00 |
| Oct 1, 2025 | HSBC | Yessica Sanchez | Buy | Initiates | $150.00 |
| Sep 22, 2025 | Evercore ISI Group | Daniel Markowitz | Outperform | Upgrade | $155.00 |
| Sep 12, 2025 | Jefferies | Matthew Stanton | Hold | Maintains | $135.00 |
| Sep 3, 2025 | HC Wainwright & Co. | Raghuram Selvaraju | Buy | Reiterates | $180.00 |
| Jul 30, 2025 | RBC Capital | Conor McNamara | Outperform | Maintains | $204.00 |
| Jul 30, 2025 | Wells Fargo | Brandon Couillard | Overweight | Maintains | $175.00 |
| Jul 22, 2025 | Stephens & Co. | Steven Etoch | Overweight | Assumes | $160.00 |
| Jul 8, 2025 | Evercore ISI Group | Daniel Markowitz | In-Line | Maintains | $130.00 |
| Jun 24, 2025 | Barclays | Luke Sergott | Overweight | Initiates | $150.00 |
| May 5, 2025 | HC Wainwright & Co. | Raghuram Selvaraju | Buy | Reiterates | $180.00 |
| Apr 30, 2025 | RBC Capital | Conor McNamara | Outperform | Maintains | $189.00 |
| Apr 29, 2025 | JP Morgan | Rachel Vatnsdal | Overweight | Maintains | $190.00 |
| Apr 17, 2025 | Canaccord Genuity | Hold | Maintains | $N/A | |
| Apr 16, 2025 | Canaccord Genuity | Kyle Mikson | Hold | Maintains | $150.00 |
| Mar 18, 2025 | Evercore ISI Group | Daniel Markowitz | In-Line | Initiates | $155.00 |
| Feb 21, 2025 | RBC Capital | Conor McNamara | Outperform | Maintains | $205.00 |
Repligen Corporation (RGEN) Competitors
The following stocks are similar to Repligen based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Repligen Corporation (RGEN) Financial Data
Repligen Corporation has a market capitalization of $9.05B with a P/E ratio of 8,040.5x. The company generates $707.89M in trailing twelve-month revenue with a 0.2% profit margin.
Revenue growth is +21.9% quarter-over-quarter, while maintaining an operating margin of +6.7% and return on equity of +0.1%.
Valuation Metrics
Market Cap
$9.05B
Enterprise Value
$9.23B
P/E Ratio
8,040.5x
PEG Ratio
-2.9x
Price/Sales
12.8x
Growth & Margins
Revenue Growth (YoY)
+21.9%
Gross Margin
+53.2%
Operating Margin
+6.7%
Net Margin
+0.2%
EPS Growth
+21.9%
Financial Health
Cash/Price Ratio
+8.3%
Current Ratio
8.4x
Debt/Equity
33.1x
ROE
+0.1%
ROA
+1.3%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Repligen Corporation (RGEN) Business Model
About Repligen Corporation
What They Do
Provides bioprocessing technologies for biologic drugs.
Business Model
Repligen generates revenue by supplying high-value consumable products and bioprocessing solutions to the biotechnology and pharmaceutical sectors. Their offerings include specialized items like Protein A affinity ligands and chromatography columns, which are essential for the purification of complex biologics, thus driving efficiency and yield for their clients.
Additional Information
With a global presence and a strong manufacturing base in Europe, Repligen serves major life sciences firms and contract manufacturing organizations. The company is committed to innovation through continuous investment in research and development, positioning itself as a critical partner for the growing biopharmaceutical market and the production of next-generation medicines.
Company Information
Sector
Healthcare
Industry
Medical Instruments & Supplies
Employees
1,778
CEO
Mr. Olivier Loeillot
Country
United States
IPO Year
1990
Website
www.repligen.comRepligen Corporation (RGEN) Latest News & Analysis
Featured Analysis
Powered by
Zacks Investment Research
Why Is Exact Sciences (EXAS) Up 45.4% Since Last Earnings Report?
Exact Sciences (EXAS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Dec 03, 2025
By Zacks Equity Research
Realtime BLOG
Latest News
Repligen Corporation (RGEN) Presents at Evercore 8th Annual Healthcare Conference Transcript
5 days ago
Quick Summary
Repligen Corporation (RGEN) participated in the Evercore 8th Annual Healthcare Conference, presenting updates and insights pertinent to investors.
Why It Matters
Repligen's presentation can signal its growth potential and strategic direction, influencing investor sentiment and stock performance in the healthcare sector.
Source: Seeking Alpha
Market Sentiment:
Neutral
Quick Summary
Repligen Corporation (NASDAQ:RGEN) will participate in the Evercore Healthcare Conference from December 2-4, with CFO Jason Garland speaking on December 3 at 1:20 p.m. ET.
Why It Matters
Repligen's participation in a prominent healthcare conference highlights its market presence and may influence investor sentiment, signaling potential growth and strategic insights.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Repligen Corporation (RGEN) Presents at Jefferies London Healthcare Conference 2025 Transcript
21 days ago
Quick Summary
Repligen Corporation (RGEN) will participate in the Jefferies London Healthcare Conference on November 18, 2025, at 8:30 AM EST, featuring CEO Olivier Loeillot.
Why It Matters
Repligen Corporation's participation in a major healthcare conference signals potential insights into company performance and growth strategies, influencing investor sentiment and stock valuation.
Source: Seeking Alpha
Market Sentiment:
Neutral
Repligen Corporation (RGEN) Presents at 7th Annual Wolfe Research Healthcare Conference Transcript
20 days ago
Quick Summary
Repligen Corporation (RGEN) will participate in the 7th Annual Wolfe Research Healthcare Conference on November 18, 2025, at 12:40 PM EST with CFO Jason Garland presenting.
Why It Matters
Repligen's participation in a prominent healthcare conference signals its visibility in the industry, potentially influencing investor sentiment and stock performance ahead of future announcements.
Source: Seeking Alpha
Market Sentiment:
Neutral
Quick Summary
Repligen (RGEN) is a leading bioprocess supplier with strong financials and growth potential, benefiting from industry trends and strategic acquisitions, making it attractive for long-term investors.
Why It Matters
Repligen's strong position in bioprocessing, solid financials, and strategic growth initiatives make it a compelling investment amid market volatility and industry shifts.
Source: Seeking Alpha
Market Sentiment:
Positive
Quick Summary
Repligen Corporation (RGEN) will present at the Stifel 2025 Healthcare Conference on November 11, 2025, at 10:00 AM EST, highlighting a strong quarterly performance.
Why It Matters
Repligen's positive quarterly performance mentioned at a healthcare conference may signal strong financial health and growth potential, influencing investor sentiment and stock performance.
Source: Seeking Alpha
Market Sentiment:
Neutral
Frequently Asked Questions About RGEN Stock
What is Repligen Corporation's (RGEN) stock forecast for 2026?
Based on our analysis of 23 Wall Street analysts, Repligen Corporation (RGEN) has a median price target of $187.50. The highest price target is $220.00 and the lowest is $160.00.
Is RGEN stock a good investment in 2026?
According to current analyst ratings, RGEN has 16 Buy ratings, 5 Hold ratings, and 0 Sell ratings. The stock is currently trading at $160.81. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for RGEN stock?
Wall Street analysts predict RGEN stock could reach $187.50 in the next 12 months. This represents a 16.6% increase from the current price of $160.81. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Repligen Corporation's business model?
Repligen generates revenue by supplying high-value consumable products and bioprocessing solutions to the biotechnology and pharmaceutical sectors. Their offerings include specialized items like Protein A affinity ligands and chromatography columns, which are essential for the purification of complex biologics, thus driving efficiency and yield for their clients.
What is the highest forecasted price for RGEN Repligen Corporation?
The highest price target for RGEN is $220.00 from Paul Knight at Keybanc, which represents a 36.8% increase from the current price of $160.81.
What is the lowest forecasted price for RGEN Repligen Corporation?
The lowest price target for RGEN is $160.00 from Luke Sergott at Barclays, which represents a -0.5% decrease from the current price of $160.81.
What is the overall RGEN consensus from analysts for Repligen Corporation?
The overall analyst consensus for RGEN is bullish. Out of 23 Wall Street analysts, 16 rate it as Buy, 5 as Hold, and 0 as Sell, with a median price target of $187.50.
How accurate are RGEN stock price projections?
Stock price projections, including those for Repligen Corporation, are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: December 9, 2025 7:36 AM UTC